Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005.
Romero A, Sued O, Puig T, Esteve A, Pumarola T, Casabona J, González V, Matas L, Tural C, Rodrigo I, Margall N, Domingo P, Casanova A, Ferrer E, Caballero E, Ribera E, Farré J, Puig T, Amengual MJ, Navarro G, Prat JM, Masabeu A, Simó JM, Villaverde CA, Barrufet P, Sauca MG, Ortin X, Ortí A, Navarro R, Euras JM, Vilaró J, Villà MC, Montull S, Vilanova C, Pujol F, Díaz O, Miró JM; AERI study Group. Romero A, et al. Among authors: barrufet p. Enferm Infecc Microbiol Clin. 2011 Aug-Sep;29(7):482-9. doi: 10.1016/j.eimc.2011.03.001. Epub 2011 May 2. Enferm Infecc Microbiol Clin. 2011. PMID: 21543135
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J. Podzamczer D, et al. Among authors: barrufet p. Antivir Ther. 2002 Jun;7(2):81-90. Antivir Ther. 2002. PMID: 12212928 Clinical Trial.
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
Solà R, Galeras JA, Montoliu S, Tural C, Force L, Torra S, Montull S, Castro ER, Coll S, Fuster D, Barrufet P, Sirera G, Giménez MD, Clotet B, Planas R. Solà R, et al. Among authors: barrufet p. AIDS Res Hum Retroviruses. 2006 May;22(5):393-400. doi: 10.1089/aid.2006.22.393. AIDS Res Hum Retroviruses. 2006. PMID: 16706615 Clinical Trial.
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team. Martínez E, et al. Among authors: barrufet p. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5. J Acquir Immune Defic Syndr. 2009. PMID: 19398921 Clinical Trial.
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B; MULTINEKA Study Group. Negredo E, et al. Among authors: barrufet p. Clin Infect Dis. 2009 Sep 15;49(6):892-900. doi: 10.1086/605440. Clin Infect Dis. 2009. PMID: 19663689 Clinical Trial.
Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08).
Romero A, González V, Esteve A, Martró E, Matas L, Tural C, Pumarola T, Casanova A, Ferrer E, Caballero E, Ribera E, Margall N, Domingo P, Farré J, Puig T, Sauca MG, Barrufet P, Amengual MJ, Navarro G, Navarro M, Vilaró J, Ortín X, Ortí A, Pujol F, Prat JM, Massabeu A, Simó JM, Villaverde CA, Benítez MÁ, Garcia I, Díaz O, Becerra J, Ros R, Sala R, Rodrigo I, Miró JM, Casabona J; AERI Study group. Romero A, et al. Among authors: barrufet p. Eur J Public Health. 2012 Dec;22(6):802-8. doi: 10.1093/eurpub/ckr179. Epub 2011 Dec 8. Eur J Public Health. 2012. PMID: 22158995
Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status.
Ferrer E, Curto J, Esteve A, Miro JM, Tural C, Murillas J, Segura F, Barrufet P, Casabona J, Podzamczer D; PISCIS Investigators. Ferrer E, et al. Among authors: barrufet p. J Antimicrob Chemother. 2015 Dec;70(12):3332-8. doi: 10.1093/jac/dkv272. Epub 2015 Sep 25. J Antimicrob Chemother. 2015. PMID: 26410171
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.
Casadellà M, Santos JR, Noguera-Julian M, Micán-Rivera R, Domingo P, Antela A, Portilla J, Sanz J, Montero-Alonso M, Navarro J, Masiá M, Valcarce-Pardeiro N, Ocampo A, Pérez-Martínez L, Pasquau J, Vivancos MJ, Imaz A, Carmona-Oyaga P, Muñoz-Medina L, Villar-García J, Barrufet P, Paredes R; INSTINCT Study Group. Casadellà M, et al. Among authors: barrufet p. J Antimicrob Chemother. 2020 Dec 1;75(12):3517-3524. doi: 10.1093/jac/dkaa349. J Antimicrob Chemother. 2020. PMID: 32929472
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM; PISCIS study group. Nomah DK, et al. Lancet HIV. 2021 Nov;8(11):e701-e710. doi: 10.1016/S2352-3018(21)00240-X. Epub 2021 Oct 13. Lancet HIV. 2021. PMID: 34655549 Free PMC article.
70 results